University of Texas's MD Anderson Cancer: ATR Inhibitor RP-3500 Demonstrates Safety and Early Clinical Benefit
October 09, 2021
October 09, 2021
HOUSTON, Texas, Oct. 9 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Oct. 8, 2021:
* * *
Early data from a biomarker-driven Phase I trial of ATR inhibitor RP-3500 shows encouraging results for patients with advanced solid tumors harboring selected molecular alterations
* * *
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered . . .
* * *
Early data from a biomarker-driven Phase I trial of ATR inhibitor RP-3500 shows encouraging results for patients with advanced solid tumors harboring selected molecular alterations
* * *
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered . . .